Treatment options for small cell lung cancer – do we have more choice?

Puglisi, Martina; Dolly, Saoirse; Faria, A.; Myerson, James S.; Popat, Sanjay; O’Brien, Mary

doi:10.1038/sj.bjc.6605527

Cited by 96 publications

(65 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 The study protocol was approved by an institutional review board or ethics committee at each participating centre.…”

Section: Study Design and Participantsmentioning

confidence: 99%

“…2 Although 35% to 86% of patients respond to first-line chemotherapy, disease progresses rapidly, and outcomes with second-line treatment are poor. [3][4][5][6] Standard first-line chemotherapy for SCLC is a platinum-etoposide doublet, with topotecan as second-line therapy in the United States (US) and European Union (EU) 1 and amrubicin as second-line therapy in Japan. 7 Though response rates with topotecan are 23% and 9% for platinum-sensitive and platinum-resistant/refractory patients, respectively, they are not durable.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Antonia

López-Martín

Bendell

et al. 2016

The Lancet Oncology

1,074

930

View full text Add to dashboard Cite

show abstract

“…4 The study protocol was approved by an institutional review board or ethics committee at each participating centre.…”

Section: Study Design and Participantsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Antonia

López-Martín

Bendell

et al. 2016

The Lancet Oncology

1,074

930

View full text Add to dashboard Cite

show abstract

“…Several novel molecules are presently undergoing evaluation, and represent potential future additions to the treatment repertoire for SCLC. 2 However, the chemoresistance of SCLC remains an important issue worldwide. 1 Long noncoding RNAs (lncRNAs) have been demonstrated to regulate nearly every step in the life cycle of a gene over the past few years.…”

mentioning

confidence: 99%

Long noncoding RNA-HOTAIR affects chemoresistance by regulating HOXA1 methylation in small cell lung cancer cells

Fang

Gao

Tong

et al. 2016

Laboratory Investigation

View full text Add to dashboard Cite

Homeobox (HOX) transcript antisense RNA (HOTAIR), a long intergenic noncoding RNA (lincRNA), has been reported to play an oncogenic role in various cancers including small cell lung cancer (SCLC). However, it is not known whether HOTAIR can modulate chemoresistance in SCLC. The aim of this study is to investigate the roles of HOTAIR in chemoresistance of SCLC and its possible molecular mechanism. Knockdown of HOTAIR was carried out in SCLC multidrug-resistant cell lines (H69AR and H446AR) and the parental cell lines (H69 and H446) to assess its influence on chemoresistance. The results showed that downregulation of HOTAIR increased cell sensitivity to anticancer drugs through increasing cell apoptosis and cell cycle arrest, and suppressed tumor growth in vivo. Moreover, HOXA1 methylation increased in the resistant cells using bisulfite sequencing PCR. Depletion of HOTAIR reduced HOXA1 methylation by decreasing DNMT1 and DNMT3b expression. The interaction between HOTAIR and HOXA1 was validated by RNA immunoprecipitation. Taken together, our study suggested that HOTAIR mediates chemoresistance of SCLC by regulating HOXA1 methylation and could be utilized as a potential target for new adjuvant therapies against chemoresistance.

show abstract

“…Cisplatin which was used as a reference chemotherapeutic drug for cytotoxicity studies due to its use in prostate and lung cancer treatments 11,12 and was dissolved in DMSO. External working concentrations of both extract and cisplatin were prepared by further dilution with their solvents.…”

Section: Drug Preparation and Treatmentmentioning

confidence: 99%

Morus rubra Extract Induces G1 Cell Cycle Arrest and Apoptosis in Human Lung and Prostate Cancer Cells

Turan¹,

Demir²,

Kilinç³

et al. 2017

IJPER

View full text Add to dashboard Cite

Objective: Cancer is one of the most deadly types of disease and evasion from apoptosis and unstoppable cell proliferation are accepted as its distinctive features. Many studies have evaluated the cytotoxic effect of different Morus species but, there is no study about cytotoxic effect of Morus rubra. In this study we aimed to evaluate phenolic composition, antioxidant properties and cytotoxic effect of acidified dimethyl sulfoxide extract of M. rubra (AMRE). Method: Antioxidant properties, phenolic composition and cytotoxic effect of AMRE were determined using spectrophotometric methods, HPLC, and MTT assay, respectively. Then, mechanisms of cytotoxic effect of AMRE on human prostate (PC-3) and lung (A549) cancer cells were examined in regard to cell cycle, apoptosis and mitochondrial membrane potential using flow cytometric methods. Results: Total phenolic content and reducing power values were 11.9 mg gallic acid equivalents and 42.9 mg trolox equivalents per g sample, respectively. Ascorbic and gallic acid were detected in AMRE as major antioxidant compounds. We determined that AMRE increased cell cycle arrest at G 1 phase and exhibited apoptotic features via decreasing mitochondrial membrane potential in both prostate and lung cancer cells. Conclusion: These findings demonstrate that M. rubra extract can affect the behavior of human prostate and lung cancer cells in vitro conditions, and this effect now needs to be investigated in vivo.

show abstract

Treatment options for small cell lung cancer – do we have more choice?

Abstract: Small cell lung cancer (SCLC) is a significant health problem worldwide because of its high propensity for relapse. This review discusses existing and future therapies for the treatment of SCLC.

Cited by 96 publications

References 100 publications

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Long noncoding RNA-HOTAIR affects chemoresistance by regulating HOXA1 methylation in small cell lung cancer cells

Morus rubra Extract Induces G1 Cell Cycle Arrest and Apoptosis in Human Lung and Prostate Cancer Cells

Contact Info

Product

Resources

About